


Abergel A, Hezode C, Asselah T, et al. A phase 3, global, multicenter, open-label study to investigate the efficacy of elbasvir/grazoprevir fixed-dose combination for 8 weeks in treatment-naive, HCV GT1b-infected patients, with non-severe fibrosis: STREAGER. The International Liver Congress. Paris, France; 2018.


Bottleau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who


Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size


Comarmond C, Garrido M, Pol S. Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C


Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C


Jonas MM, Lon HK, Rhee S, Gilmour SM, Gonzalez-Peralta RP, Leung D, et al. Pharmacokinetics of
glecaprevir/pibrentasvir in children with chronic HCV infection: interim analysis of part 2 of the DORA study [abstract

Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-

Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N

Jones CM, Logan J, Gladden RM, Bohm MK. Vital Signs: Demographic and substance use trends among heroin users -

Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse
2003;361(9358):662-668.

Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus
conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry.


fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J

Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L, et al.. Efficacy and safety of sofosbuvir-based

Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of

Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and

Kattakuzhy S, Gross C, Emmanuel B. Expansion of treatment for hepatitis C virus infection by task shifting to community-

• Kidney disease: improving global outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis,


Lange B, Roberts T, Cohn J. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17(Suppl 1):693.


Lawitz EJ, Gane EJ, Pearlman B, et al. Efficacy and safety of 12 wks vs 18 wks of treatment w/ GRZ and ELB w/ or without RBV for HCV GT1 infection in previously untreated pts w/ cirrhosis and pts w/ previous null response w/ or without cirrhosis (C-WORTHY), randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-1086.


Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O. Hepatitis C treatment uptake among patients who have


Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with endstage renal disease on haemodialysis or GFR


Neate R. Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. 2016;


Newsum AM, Stolte IG, van der Meer JTM. Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22(21):30540.


and rilpivirine or raltegravir [Poster #453]. In CROI. February 22-25. 2016.


analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69(2):293-300.


Reau N, Kwo PY, Rhee S. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1-6 Infection. In EASL International Liver Meeting, April. 2017.


Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to


Information sheet on naltrexone therapy [Internet]. Substance Abuse and Mental Health Services Administration; 2019. https://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone


Schwarz KB, Rosenthal P, Murray KF, et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to


Selph S, Chou R. Impact of contacting study authors on systematic review conclusions: diagnostic tests for hepatic fibrosis. 2014.


Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.

Tice JA, Chahal HS, Ollendorf DA. Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1 summary of California technology assessment forum report. JAMA Internal Medicine. 2015;175(9):1559-1560.


U.S. Congressional Budget Office. Prescription drug pricing in the private sector. 2015.


van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an
emerging sexually transmitted infection. AIDS. 2010;24(12):1799-1812.


von Felden J, Vermehren J, Ingiliz P, et al. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-


Øvrehus ALH, Blach S, Christensen PB, Gerstoft J, Weis N, Krarup H, et al.. Impact of prioritizing treatment in a high
resource setting - minimizing the burden of HCV related disease in 15 years. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). 2015::S591.